| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Metadata sheet per Sample | |||||||||||||||||||||||||
2 | ||||||||||||||||||||||||||
3 | All fields marked with * are mandatory. Enter your details in column E. | |||||||||||||||||||||||||
4 | Example values for each field is provided in column D for aid with filling the sheet. | |||||||||||||||||||||||||
5 | Make edits only in column E. Do not change the field names. | |||||||||||||||||||||||||
6 | ||||||||||||||||||||||||||
7 | Enter information and contact details of the lab, PI and submitter in submission information fields. | Example | Your sample details | |||||||||||||||||||||||
8 | ||||||||||||||||||||||||||
9 | Submission information | Platform* | Illumina NovaSeqX | Illumina NovaSeqX 10B XP flowcell PairedEnd 150 | Illumina NovaSeqX 10B XP flowcell PairedEnd 150 | |||||||||||||||||||||
10 | Project ID* | Unique ID associated to all the samples of this submission | Smith_m6A_seq | Sample 369647 | ||||||||||||||||||||||
11 | Submission date* | Date when sequencing data were upload | 1/10/2026 | 2/18/2026 | ||||||||||||||||||||||
12 | Submission author* | Person doing the submission | Jane Doe | Christoph Dieterich / Michael Jantsch | ||||||||||||||||||||||
13 | Submission author email* | Email from person doing the submission | jane.doe@university.edu | christoph.dieterich@uni-heidelberg.de | ||||||||||||||||||||||
14 | Laboratory head/PI* | PI's last name | Smith | Dieterich / Jantsch | ||||||||||||||||||||||
15 | Contact email* | PI's email or other contact email | j.smith@university.edu | christoph.dieterich@uni-heidelberg.de; Michael.Jantsch@meduniwien.ac.at | ||||||||||||||||||||||
16 | Study title* | Replicate number | m6A mapping in human cell lines | inosine detection in RNA-seq reads | ||||||||||||||||||||||
17 | Modification type* | The specific RNA modification targeted. | m6A | inosine | ||||||||||||||||||||||
18 | Modification type | If modification type selected is Other, mention the specific modification | ||||||||||||||||||||||||
19 | Modification detection strategy* | The sequencing strategy (RNA-Seq / MeRIP-Seq / m6A-seq / eCLIP / miCLIP / RIP-Seq / DART-seq / bisulfite-RNA / ICE-Seq / RiboMethSeq / other (specify)) | GLORI-seq | Other | ||||||||||||||||||||||
20 | Modification detection strategy | If modification detection strategy selected in Other, mention the specific method | plain RNA sequencing | |||||||||||||||||||||||
21 | Method specific information* | Description of method for modification detection strategy | Unmodified adenosine bases were converted to inosine (read as G during sequencing) leaving m6A bases intact (read as A during sequencing) | Inosine is interpreted as Guanosine during cDNA synthesis. Therefore any A to G differences between genomic DNA and RNA can be interpreted as an adenosine deamination event | ||||||||||||||||||||||
22 | Brief description of the sample manipulation prior to library prep* | Brief description of the manipulation | Chemical conversion of unmodified bases to inosine by glyoxal and nitrite | |||||||||||||||||||||||
23 | ||||||||||||||||||||||||||
24 | Sample RNA | Sample name* | Unique sample name associated to your submission | Smith_GM12878_GLORI_m6A | Sample 369647 | |||||||||||||||||||||
25 | Sample type* | RNA biotype | mRNA | mRNA | ||||||||||||||||||||||
26 | Sample description* | Description of the sample being processed | Poly(A) RNA was selected and fragmented from the source RNA. | Total RNA, NEB rRNA depletion kit | ||||||||||||||||||||||
27 | RIN value* | RIN value of sample prior to starting library prep | 9 | 9.7 | ||||||||||||||||||||||
28 | Replicate information* | Replicate number (of total number of replicates) | Rep1 (of 3) | 1 | ||||||||||||||||||||||
29 | ||||||||||||||||||||||||||
30 | Enter information for the appropriate epitranscriptomics method used in the experiment. | |||||||||||||||||||||||||
31 | Only enter information for one sample per method. Create multiple sheets for additional methods and samples | |||||||||||||||||||||||||
32 | ||||||||||||||||||||||||||
33 | Epitranscriptomics method | |||||||||||||||||||||||||
34 | Enzymatic method | Enzyme name | Name of the enzyme used for modification detection | APOBEC1-YTH | ||||||||||||||||||||||
35 | Enzyme vendor name | Name of the vendor from where the enzyme was sourced | Thermo Fisher Scientific | |||||||||||||||||||||||
36 | Enzyme catalog number | Catalog number of the enzyme in vendor catalog | 912902 | |||||||||||||||||||||||
37 | Units per reaction | Number of units of enzyme used per reaction | 4U | |||||||||||||||||||||||
38 | Digestion conditions | Mention specific digestion conditions | 37°C for 15 minutes | |||||||||||||||||||||||
39 | Expected conversion/cleavage site | Motif or specific cleavage/modification site of the enzyme | At C residue downstream of m6A site | |||||||||||||||||||||||
40 | Enzyme controls | mock/no-enzyme control (yes/no) | yes | |||||||||||||||||||||||
41 | ||||||||||||||||||||||||||
42 | Chemical method | Chemical reagent | Name of the chemical used for modification detection | Glyoxal and nitrite | ||||||||||||||||||||||
43 | Reagent vendor name | Name of the vendor from where the chemical was sourced | Sigma-aldrich | |||||||||||||||||||||||
44 | Reagent catalog number | Catalog number of the chemical in vendor catalog | 128465 | |||||||||||||||||||||||
45 | Concentration | Concentration of chemical used for modification detection | 0.1M | |||||||||||||||||||||||
46 | Reaction condition | Mention specific reaction conditions for modification detection | The RNA is incubated with glyoxal at an acidic pH, such as pH 6.0 (using a MES buffer), at an elevated temperature, such as 50 °C. Sodium nitrite is added to the reaction mixture. The reaction is typically carried out at the same temperature as the glyoxal treatment (e.g., 50 °C) for 5 minutes. | |||||||||||||||||||||||
47 | Quenching condition | Mention specific quenching conditions for modification detection | RNA purification | |||||||||||||||||||||||
48 | Conversion efficiency control | Provide list of spike-in or knownsite controls for measuring conversion efficiency (if any) | ||||||||||||||||||||||||
49 | ||||||||||||||||||||||||||
50 | RT enzyme based methods | RT enzyme | Name of the RT enzyme used for modification detection | TGIRT | ||||||||||||||||||||||
51 | RT primers | Choose RT primer strategy (random hexamers, oligo(dT), gene specific) | random hexamers | |||||||||||||||||||||||
52 | RT conditions | Mention specific RT conditions for RT reaction | Specific buffer conditions | |||||||||||||||||||||||
53 | RT temperature | Mention temperature and duration used for RT reaction | 60 °C x 30mins | |||||||||||||||||||||||
54 | Anti-m6A antibody | |||||||||||||||||||||||||
55 | Antibody | Antibody name | Common name of the antibody | |||||||||||||||||||||||
56 | Antibody vendor | Name of the vendor | Synaptic Systems | |||||||||||||||||||||||
57 | Antibody catalog | Catalog number from vendor for the antibody | 202 003 | |||||||||||||||||||||||
58 | Antibody host isotype | Host type of the antibody used | Rabbit IgG | |||||||||||||||||||||||
59 | Amount per reaction | Amount of antibody used per reaction | 5 µg | |||||||||||||||||||||||
60 | Incubation conditions | Description of incubation conditions such as buffer, temperature, time etc. | 4°C for 2 hours on a rotator | |||||||||||||||||||||||
61 | Bead type | Type of beads used for enrichment | Protein A/G magnetic beads | |||||||||||||||||||||||
62 | Input fraction used | fraction (%) of input used relative to IP | 10% | |||||||||||||||||||||||
63 | IgG control used | Yes/no, whether Ig control used | Yes | |||||||||||||||||||||||
64 | Cross Linking | Type of method used for cross-linking (if any) | UV 254nm | |||||||||||||||||||||||
65 | Assay name | Name of the assay performed for the sample | MeRIP | |||||||||||||||||||||||
66 | Assay type | Type of assay performed for sample | Immunoprecipitation | |||||||||||||||||||||||
67 | Assay protocol | Description of protocol performed for the assay | Attach protocol | |||||||||||||||||||||||
68 | ||||||||||||||||||||||||||
69 | Enter information related to library and library preparation method. | |||||||||||||||||||||||||
70 | ||||||||||||||||||||||||||
71 | Library | Library name* | A unique name for each library | Smith_m6A_GLORI_seq | Sample 369647 | |||||||||||||||||||||
72 | Library kit* | Sequencing kit, vendor and catalog no. of the library preparation kit | NEBNext Ultra II Directional RNA Library Prep | NEBNext 96 Unique Dual Index Primer Pairs UMI cat E787 | ||||||||||||||||||||||
73 | Library selection* | How the library was selected/enriched. | E7760 | E7878 | ||||||||||||||||||||||
74 | Library construction protocol* | Description of how the library was prepared from RNA | N/A | N/A | ||||||||||||||||||||||
75 | Adapter sequence* | Sequence of adapter used | AMPure XP beads | 718:7-314-B3:CTGGACACNNNNNNNNNNNN 518:5-362-B3:TACTGTGA | ||||||||||||||||||||||
76 | PCR cycles* | Number of PCR cycles used during library preparation | ||||||||||||||||||||||||
77 | Library size range* | Range of library fragment lengths | 300 | 412 | ||||||||||||||||||||||
78 | Replicate group* | Libraries that are replicates should have identical replicate group names | Cell_line_A_rep1 | |||||||||||||||||||||||
79 | Input library* | Yes/No. Whether the sample is an "Input" control or an "IP" / "Treated" library. | No | no | ||||||||||||||||||||||
80 | Library layout* | single-end or paired-end. | paired-end | paired end | ||||||||||||||||||||||
81 | UMI present* | Yes/No | Yes | yes | ||||||||||||||||||||||
82 | UMI pattern | Pattern of UMI used for the sample | 6N | 12N | ||||||||||||||||||||||
83 | Library enrichment method | UMI treatment, circularization, ligation specifics, PCR, etc. | PCR (12 cycles) | UMI treatment | ||||||||||||||||||||||
84 | ||||||||||||||||||||||||||
85 | Enter information related to the sequencing instrument and read statistics. | |||||||||||||||||||||||||
86 | ||||||||||||||||||||||||||
87 | Sequencing | Instrument model* | Description of the sequencer model used | Illumina NovaSeq 6000 | Illumina NovaSeqX 10B XP flowcell PairedEnd 150 | |||||||||||||||||||||
88 | Read length* | Length of read generated for the sample | 150 | 150 | ||||||||||||||||||||||
89 | Mean quality* | Mean quality of sequencing run | 35 | >30 | ||||||||||||||||||||||
90 | Read counts* | Number of reads generated for the sample | 50,000,000 | 860,400,000 | ||||||||||||||||||||||
91 | Spike ins | Any spike-in controls added (eg., ERCC RNA spike-in mix, etc.) | ERCC RNA Spike-In Mix 1 | 1% PhiX | ||||||||||||||||||||||
92 | ||||||||||||||||||||||||||
93 | Enter information of the files and md5sum for the files to be uploaded. | |||||||||||||||||||||||||
94 | Two fastq files for paired end read sequencing and one fastq file for single end read sequencing is expected. | |||||||||||||||||||||||||
95 | If more files are to be uploaded, add rows below. | |||||||||||||||||||||||||
96 | ||||||||||||||||||||||||||
97 | File | File name* | Unique file name of the uploaded file | Smith_m6A_GLORI_seq_rep1_R1.fastq.gz | 23GCFKLT3_7_R19973_20260116.tar.gz | |||||||||||||||||||||
98 | File MD5sum* | MD5sum for the uploaded file | d41d8cd98f00b204e9800998ecf8427e | |||||||||||||||||||||||
99 | File name | Unique file name of the uploaded file | Smith_m6A_GLORI_seq_rep1_R2.fastq.gz | 23GCFKLT3_7_R19973_20260116.tar.gz | ||||||||||||||||||||||
100 | File MD5sum | MD5sum for the uploaded file | a51d8dd983005203e98f09ff8fcf8j27ae | |||||||||||||||||||||||